Providers
Treating COVID-19 with Seraph 100
The Seraph 100 binds with SARS-CoV-2, the virus that causes COVID-19. Clinicians have reported a reduction in inflammatory markers such as IL-6, d-dimer, and ferritin. Other anecdotal observations include improved hemodynamic stabilization, reduction of vasopressors and fractionally inspired oxygen, and avoidance or reduced time of mechanical ventilation.
The Seraph 100:
- Is the first device with an indication to reduce pathogens in the bloodstream in adjunction to antibiotic therapy*
- Reduces a broad spectrum of drug-susceptible and drug-resistant pathogens
- Can be used as an early intervention prior to pathogen identification
- Has a novel biomimetic binding surface that prevents bacteria from developing resistance from it
Timestamps
00:00: Introductions
00:50: Seraph 100 Overview to Treat COVID-19 by Dr. Mink Chawla
12:35: Clinical Practice & Use of the Seraph 100 by Dr. Sean Barnett
35:50: Questions and Answers
Clinical Practice and Hands-On Experience:
User Case Study Presentations
Seraph 100 User Group III –
September 28, 2020
Clinicians review latest cases from Eisenhower Medical Center
Timestamps
00:00: Case Discussion
02:43: Introduction
03:45: Product Overview
06:44: Case Study Presentation
25:40: Q&A
Seraph 100 User Group II – September 4, 2020
Clinicians review COVID-19 Cases from Forrest General
Timestamps
00:00: Introduction 01:45: Product Overview
16:38: Case Study Presentation
37:34: Q&A
Seraph 100 in the Field
Seraph 100 Microbind Affinity Blood Filter Technology
Seraph 100 is being used in hospitals across the United States, including several military hospitals. Several hospitals have presented their findings:
Walter Reed Medical Center: Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter
Brooke Army Medical Center: USU COVID – 19 Clinical Performance Improvement Conference #19 Severe ARDS secondary to COVID Pneumonia
Dwight D. Eisenhower Army Medical Center: USU COVID – 19 Clinical Performance Improvement Conference #19 Seraph 100 Case Reports
Providers Using Seraph 100
in the United States
Please read our information sheet to learn more about the device and how to order it.
For FDA guidance on the use of Seraph 100 on COVID-19 patients, please follow the links below:
NOVEMBER 23, 2021
Extracorporeal Pathogen Adsorption for the Treatment of Bloodstream Infections in the Critically Ill
SEPTEMBER 14, 2021
Sepsis Alliance: Hope for Critically Ill COVID-19 Patients
JUNE 9, 2021
Clinical Use and Lessons Learned with Seraph 100
MAY 17, 2021
COVID-19 Webinar: A Role for Seraph 100
NOVEMBER 11, 2020
More Than Pathogen Reduction – Seraph 100 in COVID-19
JUNE 24, 2020
COVID-19 Webinar: A Role for Seraph 100